QQ客服 官方微博 反馈留言

	Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women
	Yang, Chen; Zhao, Mingdong; Zhu, Ying; Su, Jinsong; Yang, Ruikun; Lai, Jiajie; Xu, Bo; Liang, Guanzhao
刊名	BMC GASTROENTEROLOGY
	2019
卷号	19
关键词	Capecitabine Bevacizumab Colorectal cancer Progression-free survival Overall survival
ISSN号	1471-230X
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3594398
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Yang, Chen,Zhao, Mingdong,Zhu, Ying,et al. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women[J]. BMC GASTROENTEROLOGY,2019,19.
APA	Yang, Chen.,Zhao, Mingdong.,Zhu, Ying.,Su, Jinsong.,Yang, Ruikun.,...&Liang, Guanzhao.(2019).Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women.BMC GASTROENTEROLOGY,19.
MLA	Yang, Chen,et al."Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women".BMC GASTROENTEROLOGY 19(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。